FAAH inhibitors

Leveraging and Enhancing Natural Therapeutics

Anandamide is deactivated by the enzyme FAAH (fatty acid amide hydrolase), which is an attractive pharmaceutical target. Research pioneered by Exxel Pharma’s CSO, Daniele Piomelli, and other academic labs, has shown that FAAH-mediated deactivation of anandamide can be blocked by small molecules. Inhibition of FAAH increases anandamide levels and signaling, thereby boosting the protective effects of the endocannabinoid system.

Exxel Pharma’s URB597 and URB937 are examples of small molecule therapeutics that enhance anandamide signaling by blocking FAAH, thereby promoting different therapeutic effects. Some of the clinical applications of FAAH inhibition include pain management, addiction, anxiety, PTSD and insomnia.

Key Advantages over cannabis based products

 

Synthetic

Patented

Documented safety profile

Easy dosage

Free of drug-drug interactions

Legal with FDA approval

Key Publications

A list of published URB937 data, including work from international, academic research laboratories, can be found here.

Published URB597 data, including work from international, academic research laboratories, can be found here.

For more information, please contact us.